Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Sensyne Health appoints President, North America

13th Nov 2020 07:00

RNS Number : 1982F
Sensyne Health PLC
13 November 2020
 

Sensyne Health appoints President, North America, to

lead US expansion

 

 

Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company's North American operations, building Sensyne's presence in the US and recruiting a US-based team.

Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner.

Derek is a US national and will be based in the US.  

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"I'm delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business."

Derek Baird, said:

"I've been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I'm excited to bring the Sensyne vision and unique business model to the US market."

 

 

-ENDS-

 

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

CSC[email protected]

 

About Sensyne Health 

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADGBDBUXBDGGD

Related Shares:

SENS.L
FTSE 100 Latest
Value8,809.74
Change53.53